Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...

Tandem and Eli Lilly carried out trials to demonstrate the advantages of using Lyumjev in combination with Control-IQ ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11.17 billion by 2032, from US$ 7.36 billion in 2023. The market is mainly driven by growth rate of diabetes ...

Arecor Presents Positive Data From Phase I Clinical Trial Of Ultra-Concentrated Ultra-Rapid Acting Insulin At278 In ...

Tandem Diabetes Care ( TNDM 4.25%) had some encouraging news to report on the regulatory front Thursday, and after it hit the ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Rapid Acting Insulin market Report, Forecast by Product, Indication, Distribution Channel, Countries and Company ...

Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Rapid Acting Insulin Market Report, Forecast by Product, Indication, Distribution Channel, Countries and Company Analysis 2024-2032" report has been ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Diabetics who fly with an insulin pump could find themselves with lower-than-normal blood sugar levels, a new study sa ...

Altitude changes during commercial flights may affect the blood glucose levels of people with type 1 diabetes who are treated ...